{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T09:07:13Z","timestamp":1780564033313,"version":"3.54.1"},"reference-count":82,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2014,1,3]],"date-time":"2014-01-03T00:00:00Z","timestamp":1388707200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2014,1,3]],"date-time":"2014-01-03T00:00:00Z","timestamp":1388707200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Bayer HealthCare Pharmaceuticals"},{"DOI":"10.13039\/100017183","name":"Janssen Scientific Affairs, LLC","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017183","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Pharm Ther"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1111\/jcpt.12122","type":"journal-article","created":{"date-parts":[[2014,1,3]],"date-time":"2014-01-03T09:40:51Z","timestamp":1388742051000},"page":"118-135","source":"Crossref","is-referenced-by-count":30,"title":["Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions"],"prefix":"10.1155","volume":"39","author":[{"given":"J. W.","family":"Cheng","sequence":"first","affiliation":[{"name":"MCPHS University; Brigham and Women's Hospital; Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Barillari","sequence":"additional","affiliation":[{"name":"Centre for Haemorrhagic and Thrombotic Diseases; University Hospital; Udine Udine Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,1,3]]},"reference":[{"key":"10.1111\/jcpt.12122-BIB0001|jcpt12122-cit-0001","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/0735-1097(92)90473-Z","article-title":"Pulmonary embolism thrombolysis: a clarion call for international collaboration","volume":"19","author":"Goldhaber","year":"1992","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/jcpt.12122-BIB0002|jcpt12122-cit-0002","first-page":"e257","article-title":"ACC\/AHA\/ESC 2006 guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society","volume":"114","author":"Fuster","year":"2006","journal-title":"Circulation"},{"key":"10.1111\/jcpt.12122-BIB0003|jcpt12122-cit-0003","first-page":"e2","article-title":"Heart disease and stroke statistics - 2012 update: a report from the American Heart Association","volume":"125","author":"Roger","year":"2012","journal-title":"Circulation"},{"key":"10.1111\/jcpt.12122-BIB0004|jcpt12122-cit-0004","doi-asserted-by":"crossref","first-page":"e44S","DOI":"10.1378\/chest.11-2292","article-title":"Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"Ageno","year":"2012","journal-title":"Chest"},{"key":"10.1111\/jcpt.12122-BIB0005|jcpt12122-cit-0005","doi-asserted-by":"crossref","first-page":"e531S","DOI":"10.1378\/chest.11-2304","article-title":"Antithrombotic therapy for atrial fibrillation: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"You","year":"2012","journal-title":"Chest"},{"key":"10.1111\/jcpt.12122-BIB0006|jcpt12122-cit-0006","unstructured":"Boehringer Ingelheim International GmbH Pradaxa \u00ae (dabigatran etexilate) Summary of Product Characteristics 2013 http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000829\/WC500041059.pdf"},{"key":"10.1111\/jcpt.12122-BIB0007|jcpt12122-cit-0007","unstructured":"Boehringer Ingelheim Pharmaceuticals Inc Pradaxa \u00ae (dabigatran etexilate) Prescribing Information 2013 http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/022512s017lbl.pdf"},{"key":"10.1111\/jcpt.12122-BIB0008|jcpt12122-cit-0008","unstructured":"Boehringer Ingelheim Canada Ltd Pradax\u2122 (dabigatran etexilate mesilate) Product Monograph 2013 http:\/\/www.boehringer-ingelheim.ca\/content\/dam\/internet\/opu\/ca_EN\/documents\/humanhealth\/product_monograph\/Pradax-pm.pdf"},{"key":"10.1111\/jcpt.12122-BIB0009|jcpt12122-cit-0009","unstructured":"Bayer Pharma AG Xarelto \u00ae (rivaroxaban) Summary of Product Characteristics 2013 http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000944\/WC500057108.pdf"},{"key":"10.1111\/jcpt.12122-BIB0010|jcpt12122-cit-0010","unstructured":"Janssen Pharmaceuticals Inc Xarelto \u00ae (rivaroxaban) Prescribing Information 2013 http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/022406s004lbl.pdf"},{"key":"10.1111\/jcpt.12122-BIB0011|jcpt12122-cit-0011","unstructured":"Bayer Inc Product Monograph (Canada) 2013 http:\/\/www.bayer.ca\/files\/XARELTO-PM-ENG-28AUG2013-164839.pdf?#"},{"key":"10.1111\/jcpt.12122-BIB0012|jcpt12122-cit-0012","unstructured":"Bristol-Myers Squibb, Pfizer EEIG Eliquis \u00ae (apixaban) Summary of Product Characteristics 2013 http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002148\/WC500107728.pdf"},{"key":"10.1111\/jcpt.12122-BIB0013|jcpt12122-cit-0013","unstructured":"Bristol-Myers Squibb Company, Pfizer Inc. Eliquis \u00ae (apixaban) Prescribing Information 2012 http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/202155s000lbl.pdf"},{"key":"10.1111\/jcpt.12122-BIB0014|jcpt12122-cit-0014","unstructured":"Bristol-Myers Squibb Canada Inc, Pfizer Canada Inc. Eliquis (apixaban) Product Monograph 2012 http:\/\/www.bmscanada.ca\/static\/products\/en\/pm_pdf\/ELIQUIS_EN_PM.pdf"},{"key":"10.1111\/jcpt.12122-BIB0015|jcpt12122-cit-0015","unstructured":"Medscape EU Approves Xarelto for Secondary Prevention after an ACS 2013 http:\/\/www.medscape.com\/viewarticle\/804734"},{"key":"10.1111\/jcpt.12122-BIB0016|jcpt12122-cit-0016","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1161\/CIRCULATIONAHA.109.853119","article-title":"New anticoagulants","volume":"121","author":"Eikelboom","year":"2010","journal-title":"Circulation"},{"key":"10.1111\/jcpt.12122-BIB0017|jcpt12122-cit-0017","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1021\/jm0109513","article-title":"Structure-based design of novel potent nonpeptide thrombin inhibitors","volume":"45","author":"Hauel","year":"2002","journal-title":"J Med Chem"},{"key":"10.1111\/jcpt.12122-BIB0018|jcpt12122-cit-0018","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nrd3185","article-title":"The discovery and development of rivaroxaban, an oral, direct Factor Xa inhibitor","volume":"10","author":"Perzborn","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"10.1111\/jcpt.12122-BIB0019|jcpt12122-cit-0019","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/j.1538-7836.2008.02939.x","article-title":"Apixaban, an oral, direct and highly selective Factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies","volume":"6","author":"Wong","year":"2008","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jcpt.12122-BIB0020|jcpt12122-cit-0020","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1007\/s11239-011-0551-3","article-title":"Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor","volume":"31","author":"Wong","year":"2011","journal-title":"J Thromb Thrombolysis"},{"key":"10.1111\/jcpt.12122-BIB0021|jcpt12122-cit-0021","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1124\/dmd.107.019083","article-title":"The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans","volume":"36","author":"Blech","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1111\/jcpt.12122-BIB0022|jcpt12122-cit-0022","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.clpt.2005.06.011","article-title":"Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct Factor Xa inhibitor","volume":"78","author":"Kubitza","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/jcpt.12122-BIB0023|jcpt12122-cit-0023","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1124\/dmd.108.025569","article-title":"Metabolism and excretion of rivaroxaban, an oral, direct Factor Xa inhibitor, in rats, dogs and humans","volume":"37","author":"Weinz","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1111\/jcpt.12122-BIB0024|jcpt12122-cit-0024","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1124\/dmd.108.023143","article-title":"Apixaban metabolism and pharmacokinetics after oral administration to humans","volume":"37","author":"Raghavan","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1111\/jcpt.12122-BIB0025|jcpt12122-cit-0025","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/ki.2008.698","article-title":"For estimating creatinine clearance measuring muscle mass gives better results than those based on demographics","volume":"75","author":"Rule","year":"2009","journal-title":"Kidney Int"},{"key":"10.1111\/jcpt.12122-BIB0026|jcpt12122-cit-0026","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1160\/TH11-08-0551","article-title":"Pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects after oral administration of dabigatran etexilate","volume":"107","author":"H\u00e4rtter","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1111\/jcpt.12122-BIB0027|jcpt12122-cit-0027","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1177\/0091270008324179","article-title":"Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment","volume":"48","author":"Stangier","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"10.1111\/jcpt.12122-BIB0028|jcpt12122-cit-0028","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2165\/11318170-000000000-00000","article-title":"Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study","volume":"49","author":"Stangier","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"10.1111\/jcpt.12122-BIB0029|jcpt12122-cit-0029","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s00228-005-0043-5","article-title":"Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 - an oral, direct Factor Xa inhibitor - after multiple dosing in healthy male subjects","volume":"61","author":"Kubitza","year":"2005","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1111\/jcpt.12122-BIB0030|jcpt12122-cit-0030","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2165\/00003088-200847030-00006","article-title":"Population pharmacokinetics and pharmacodynamics of rivaroxaban - an oral, direct Factor Xa inhibitor - in patients undergoing major orthopaedic surgery","volume":"47","author":"Mueck","year":"2008","journal-title":"Clin Pharmacokinet"},{"key":"10.1111\/jcpt.12122-BIB0031|jcpt12122-cit-0031","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1185\/03007990802361499","article-title":"Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects","volume":"24","author":"Kubitza","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1111\/jcpt.12122-BIB0032|jcpt12122-cit-0032","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/jcph.5","article-title":"The influence of age and gender on the pharmacokinetics and pharmacodynamics of rivaroxaban - an oral, direct Factor Xa inhibitor","volume":"53","author":"Kubitza","year":"2013","journal-title":"J Clin Pharmacol"},{"key":"10.1111\/jcpt.12122-BIB0033|jcpt12122-cit-0033","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1160\/TH09-03-0196","article-title":"Safety, pharmacokinetics and pharmacodynamics of single doses of rivaroxaban - an oral, direct Factor Xa inhibitor - in elderly Chinese subjects","volume":"103","author":"Jiang","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1111\/jcpt.12122-BIB0034|jcpt12122-cit-0034","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1177\/0091270006296058","article-title":"Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects","volume":"47","author":"Kubitza","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"10.1111\/jcpt.12122-BIB0035|jcpt12122-cit-0035","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/bcp.12054","article-title":"Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban - an oral, direct Factor Xa inhibitor","volume":"76","author":"Kubitza","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/jcpt.12122-BIB0036|jcpt12122-cit-0036","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1365-2125.2009.03390.x","article-title":"Safety, pharmacokinetics and pharmacodynamics of single\/multiple doses of the oral, direct Factor Xa inhibitor rivaroxaban in healthy Chinese subjects","volume":"68","author":"Zhao","year":"2009","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/jcpt.12122-BIB0037|jcpt12122-cit-0037","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2133\/dmpk.DMPK-12-RG-034","article-title":"Model-based dose selection for phase III rivaroxaban study in Japanese patients with non-valvular atrial fibrillation","volume":"28","author":"Tanigawa","year":"2013","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1111\/jcpt.12122-BIB0038|jcpt12122-cit-0038","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/j.1365-2125.2010.03753.x","article-title":"Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor","volume":"70","author":"Kubitza","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/jcpt.12122-BIB0039|jcpt12122-cit-0039","doi-asserted-by":"crossref","first-page":"335","DOI":"10.5414\/CPP45335","article-title":"Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban - an oral, direct Factor Xa inhibitor - in healthy subjects","volume":"45","author":"Mueck","year":"2007","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1111\/jcpt.12122-BIB0040|jcpt12122-cit-0040","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1177\/0091270006286904","article-title":"Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct Factor Xa inhibitor, in healthy subjects","volume":"46","author":"Kubitza","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"10.1111\/jcpt.12122-BIB0041|jcpt12122-cit-0041","doi-asserted-by":"crossref","first-page":"549","DOI":"10.5414\/CP201812","article-title":"The effect of food on the absorption and pharmacokinetics of rivaroxaban","volume":"51","author":"Stampfuss","year":"2013","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1111\/jcpt.12122-BIB0042|jcpt12122-cit-0042","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1111\/bcp.12114","article-title":"Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects","volume":"76","author":"Upreti","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/jcpt.12122-BIB0043|jcpt12122-cit-0043","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/j.1365-2125.2012.04369.x","article-title":"Apixaban, an oral, direct Factor Xa inhibitor: single-dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects","volume":"75","author":"Frost","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/jcpt.12122-BIB0044|jcpt12122-cit-0044","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1365-2125.2007.02899.x","article-title":"The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects","volume":"64","author":"Stangier","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/jcpt.12122-BIB0045|jcpt12122-cit-0045","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2165\/00003088-200847010-00005","article-title":"Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects","volume":"47","author":"Stangier","year":"2008","journal-title":"Clin Pharmacokinet"},{"key":"10.1111\/jcpt.12122-BIB0046|jcpt12122-cit-0046","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/MBC.0b013e32834f1b0c","article-title":"Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran","volume":"23","author":"Stangier","year":"2012","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1111\/jcpt.12122-BIB0047|jcpt12122-cit-0047","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1160\/TH09-03-0176","article-title":"Assessment of laboratory assays to measure rivaroxaban - an oral, direct Factor Xa inhibitor","volume":"103","author":"Samama","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1111\/jcpt.12122-BIB0048|jcpt12122-cit-0048","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1097\/FTD.0b013e3181f2f264","article-title":"Assays for measuring rivaroxaban: their suitability and limitations","volume":"32","author":"Lindhoff-Last","year":"2010","journal-title":"Ther Drug Monit"},{"key":"10.1111\/jcpt.12122-BIB0049|jcpt12122-cit-0049","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1160\/TH11-12-0832","article-title":"Accurate determination of rivaroxaban levels requires different calibrator sets but not addition of antithrombin","volume":"108","author":"Mani","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1111\/jcpt.12122-BIB0050|jcpt12122-cit-0050","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1160\/TH11-06-0391","article-title":"Evaluation of the anti-Factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls","volume":"107","author":"Samama","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1111\/jcpt.12122-BIB0051|jcpt12122-cit-0051","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00228-012-1304-8","article-title":"Pharmacokinetic and pharmacodynamic effects of comedication of clopidogrel and dabigatran etexilate in healthy male volunteers","volume":"69","author":"Hartter","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1111\/jcpt.12122-BIB0052|jcpt12122-cit-0052","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1111\/j.1365-2125.2012.04453.x","article-title":"Oral bioavailability of dabigatran etexilate (Pradaxa\u00ae) after co-medication with verapamil in healthy subjects","volume":"75","author":"Hartter","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/jcpt.12122-BIB0053|jcpt12122-cit-0053","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1365-2125.2012.04218.x","article-title":"Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin","volume":"74","author":"H\u00e4rtter","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/jcpt.12122-BIB0054|jcpt12122-cit-0054","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1124\/dmd.108.025551","article-title":"In vitro metabolism of rivaroxaban - an oral, direct Factor Xa inhibitor - in liver microsomes and hepatocytes of rat, dog and man","volume":"37","author":"Lang","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1111\/jcpt.12122-BIB0055|jcpt12122-cit-0055","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/bcp.12075","article-title":"Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects","volume":"76","author":"Mueck","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/jcpt.12122-BIB0056|jcpt12122-cit-0056","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1177\/030006051204000508","article-title":"Absence of clinically relevant interactions between rivaroxaban - an oral, direct Factor Xa inhibitor - and digoxin or atorvastatin in healthy subjects","volume":"40","author":"Kubitza","year":"2012","journal-title":"J Int Med Res"},{"key":"10.1111\/jcpt.12122-BIB0057|jcpt12122-cit-0057","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1365-2125.2006.02776.x","article-title":"Rivaroxaban (BAY 59-7939) - an oral, direct Factor Xa inhibitor - has no clinically relevant interaction with naproxen","volume":"63","author":"Kubitza","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/jcpt.12122-BIB0058|jcpt12122-cit-0058","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3390\/ph5030279","article-title":"Effect of co-administration of rivaroxaban and clopidogrel on bleeding time, pharmacodynamics and pharmacokinetics: a phase I study","volume":"5","author":"Kubitza","year":"2012","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1111\/jcpt.12122-BIB0059|jcpt12122-cit-0059","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1177\/0091270006292127","article-title":"Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban - an oral, direct Factor Xa inhibitor - are not affected by aspirin","volume":"46","author":"Kubitza","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"10.1111\/jcpt.12122-BIB0060|jcpt12122-cit-0060","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/cpdd.26","article-title":"Investigation of pharmacodynamic and pharmacokinetic interactions between rivaroxaban and enoxaparin in healthy male subjects","volume":"2","author":"Kubitza","year":"2013","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1111\/jcpt.12122-BIB0061|jcpt12122-cit-0061","first-page":"59","article-title":"Effect of famotidine on the pharmacokinetics of apixaban, an oral direct Factor Xa inhibitor","volume":"5","author":"Upreti","year":"2013","journal-title":"Clin Pharmacol"},{"key":"10.1111\/jcpt.12122-BIB0062|jcpt12122-cit-0062","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12122-BIB0063|jcpt12122-cit-0063","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12122-BIB0064|jcpt12122-cit-0064","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12122-BIB0065|jcpt12122-cit-0065","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation","volume":"364","author":"Connolly","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12122-BIB0066|jcpt12122-cit-0066","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1161\/CIRCULATIONAHA.112.001139","article-title":"The long-term multicenter observational study of dabigatran treatment in patients with atrial fibrillation (RELY-ABLE) study","volume":"128","author":"Connolly","year":"2013","journal-title":"Circulation"},{"key":"10.1111\/jcpt.12122-BIB0067|jcpt12122-cit-0067","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1253\/circj.CJ-12-0454","article-title":"Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation - the J-ROCKET AF study","volume":"76","author":"Hori","year":"2012","journal-title":"Circ J"},{"key":"10.1111\/jcpt.12122-BIB0068|jcpt12122-cit-0068","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12122-BIB0069|jcpt12122-cit-0069","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1105819","article-title":"Apixaban with antiplatelet therapy after acute coronary syndrome","volume":"365","author":"Alexander","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12122-BIB0070|jcpt12122-cit-0070","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1097\/EJA.0b013e32833f6f6f","article-title":"Regional anaesthesia and antithrombotic agents: recommendations of the European Society of Anaesthesiology","volume":"27","author":"Gogarten","year":"2010","journal-title":"Eur J Anaesthesiol"},{"key":"10.1111\/jcpt.12122-BIB0071|jcpt12122-cit-0071","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.acvd.2011.09.001","article-title":"Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: thrombin or Factor-Xa inhibitors. Recommendations of the Working Group on Perioperative Haemostasis and the French Study Group on Thrombosis and Haemostasis","volume":"104","author":"Si\u00e9","year":"2011","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1111\/jcpt.12122-BIB0072|jcpt12122-cit-0072","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","article-title":"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism","volume":"366","author":"The EINSTEIN-PE Investigators","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12122-BIB0073|jcpt12122-cit-0073","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1515\/CCLM.2011.134","article-title":"Laboratory assessment of new anticoagulants","volume":"49","author":"Samama","year":"2011","journal-title":"Clin Chem Lab Med"},{"key":"10.1111\/jcpt.12122-BIB0074|jcpt12122-cit-0074","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.thromres.2005.12.002","article-title":"Hemostatic effect of activated factor VII without promotion of thrombus growth in melagatran-anticoagulated primates","volume":"119","author":"Gruber","year":"2007","journal-title":"Thromb Res"},{"key":"10.1111\/jcpt.12122-BIB0075|jcpt12122-cit-0075","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/ALN.0b013e318238c036","article-title":"Evaluation of prothrombin complex concentrate and recombinant activated Factor VII to reverse rivaroxaban in a rabbit model","volume":"116","author":"Godier","year":"2012","journal-title":"Anesthesiology"},{"key":"10.1111\/jcpt.12122-BIB0076|jcpt12122-cit-0076","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1111\/j.1538-7836.2012.04859.x","article-title":"Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P\/N) in a rabbit model","volume":"10","author":"Pragst","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jcpt.12122-BIB0077|jcpt12122-cit-0077","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1161\/CIRCULATIONAHA.111.029017","article-title":"Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects","volume":"124","author":"Eerenberg","year":"2011","journal-title":"Circulation"},{"key":"10.1111\/jcpt.12122-BIB0078|jcpt12122-cit-0078","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1160\/TH12-03-0179","article-title":"Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban. A randomised crossover ex vivo study in healthy volunteers","volume":"108","author":"Marlu","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1111\/jcpt.12122-BIB0079|jcpt12122-cit-0079","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/clc.22037","article-title":"Emergency management of bleeding associated with old and new oral anticoagulants","volume":"35","author":"Peacock","year":"2012","journal-title":"Clin Cardiol"},{"key":"10.1111\/jcpt.12122-BIB0080|jcpt12122-cit-0080","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nm.3102","article-title":"A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation Factor Xa","volume":"19","author":"Lu","year":"2013","journal-title":"Nat Med"},{"key":"10.1111\/jcpt.12122-BIB0081|jcpt12122-cit-0081","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood-2012-11-468207","article-title":"A specific antidote for dabigatran: functional and structural characterization","volume":"121","author":"Schiele","year":"2013","journal-title":"Blood"},{"key":"10.1111\/jcpt.12122-BIB0082|jcpt12122-cit-0082","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2165\/00003088-200847050-00001","article-title":"Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate","volume":"47","author":"Stangier","year":"2008","journal-title":"Clin Pharmacokinet"}],"container-title":["Journal of Clinical Pharmacy and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjcpt.12122","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjcpt.12122","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/jcpt.12122\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T18:05:11Z","timestamp":1671818711000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jcpt.12122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,3]]},"references-count":82,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,4]]}},"URL":"https:\/\/doi.org\/10.1111\/jcpt.12122","archive":["Portico"],"relation":{},"ISSN":["0269-4727"],"issn-type":[{"value":"0269-4727","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1,3]]}}}